2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-174835
    hCA-I/hCA-II-IN-1
    hCA-I/hCA-II-IN-1 (Compound P4) is a potent dual human carbonic anhydrase I (hCA-I) and human carbonic anhydrase II (hCA-II) inhibitor with Ki values of 0.22 μM and 0.33 μM, respectively. hCA-I/hCA-II-IN-1 can be used in research on diseases related to CA enzymes such as glaucoma, hypertension, and ulcers.
    hCA-I/hCA-II-IN-1
  • HY-17494B
    Timolol hemimaleate 33305-95-2 98%
    Timolol ((S)-L-714,465; MK 950) hemimaleate is a β-blocker available for both topical and systemic administration. Topical Timolol hemimaleate is primarily used to reduce intraocular pressure with open-angle glaucoma and ocular hypertension. Timolol hemimaleate can also be used for the research of infantile hemangiomas, hypertension, myocardial infarction, migraine prophylaxis, and atrial fibrillation.Timolol also has cardioprotective effect.
    Timolol hemimaleate
  • HY-17494R
    Timolol (Standard) 26839-75-8
    Timolol (Standard) is the analytical standard of Timolol. This product is intended for research and analytical applications. Timolol is a β-blocker available for both topical and systemic administration. Topical Timolol is primarily used to reduce intraocular pressure with open-angle glaucoma and ocular hypertension. Timolol can also be used for the research of infantile hemangiomas, hypertension, myocardial infarction, migraine prophylaxis, and atrial fibrillation.Timolol also has cardioprotective effect.
    Timolol (Standard)
  • HY-17497S
    Acebutolol-d7 2701782-36-5 98%
    Acebutolol-d7 is a deuterium labeled Acebutolol. Acebutolol is a selective β1 adrenergic receptor antagonist used in the treatment of hypertension, angina pectoris and cardiac arrhythmias.
    Acebutolol-d7
  • HY-174986
    CGRP antagonist 7 2173508-07-9 98%
    CGRP antagonist 7 is a potent calcitonin gene-related peptide receptor (CGRP) antagonist with a Ki of 0.029 nM. CGRP antagonist 7 Inhibit the production of cyclic adenosine monophosphate (cAMP) with an IC50 of 1.5 nM. CGRP antagonist 7 can be used for the study of migraine.
    CGRP antagonist 7
  • HY-17498B
    Atenolol hydrochloride 51706-40-2 98%
    Atenolol hydrochloride is a cardioselective β1-adrenergic receptor blocker, with a Ki of 697 nM at β1-adrenoceptor in guine pig left ventricle membrane. Atenolol hydrochloride can be used for the research of hypertension and angina pectoris.
    Atenolol hydrochloride
  • HY-175018
    VEGFR-2-IN-71 98%
    VEGFR-2-IN-71 is a dual VEGFR2/tubulin inhibitor. VEGFR-2-IN-71 inhibits tumor cell proliferation and induces apoptosis and cell cycle arrest. VEGFR-2-IN-71 inhibits angiogenesis in the chick chorioallantoic membrane (CAM) model. VEGFR-2-IN-71 inhibits tumor growth in the HGC-27 xenograft model by inhibiting VEGFR2 and tubulin. VEGFR-2-IN-71 has low oral bioavailability in rats. VEGFR-2-IN-71 can be used in cancer research.
    VEGFR-2-IN-71
  • HY-17502S
    Simvastatin-d11 1002347-74-1 98%
    Simvastatin-d11 is the deuterium labeled Simvastatin. Simvastatin (MK 733) is a competitive inhibitor of HMG-CoA reductase with a Ki of 0.2 nM.
    Simvastatin-d11
  • HY-17503C
    Metoprolol fumarate 80274-67-5 98%
    Metoprolol fumarate (CGP 2175C) is an orally active, selective β1-adrenoceptor antagonist. Metoprolol fumarate shows anti-inflammation, antitumor and anti-angiogenic properties.
    Metoprolol fumarate
  • HY-17504C
    (3R,5R)-Rosuvastatin 1094100-06-7 98%
    (3R,5R)-Rosuvastatin is the (3R,5R)-enantiomer of Rosuvastatin. Rosuvastatin is a competitive HMG-CoA reductase inhibitor with an IC50 of 11 nM. Rosuvastatin potently blocks human ether-a-go-go related gene (hERG) current with an IC50 of 195 nM. Rosuvastatin reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin is very effective in lowering low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels.
    (3R,5R)-Rosuvastatin
  • HY-17504D
    (3S,5R)-Rosuvastatin 1242184-42-4 98%
    (3S,5R)-Rosuvastatin is the (3S,5R)-enantiomer of Rosuvastatin. Rosuvastatin is a competitive HMG-CoA reductase inhibitor with an IC50 of 11 nM. Rosuvastatin potently blocks human ether-a-go-go related gene (hERG) current with an IC50 of 195 nM. Rosuvastatin reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin is very effective in lowering low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels.
    (3S,5R)-Rosuvastatin
  • HY-175217
    Nrf2 activator-20 89883-16-9 98%
    Nrf2 activator-20 is a potent Nrf2 activator with anti-inflammatory and antioxidant activities. Nrf2 activator-20 activates the anti-inflammatory pathway by interfering with the Keap1-Nrf2 interaction and is beneficial in vivo. Nrf2 activator-20 can be used for the study of acute respiratory distress syndrome (ARDS) and ischemia-reperfusion injury.
    Nrf2 activator-20
  • HY-175327
    LIBX-A402
    LIBX-A402 (Compound 15b) is a selective ACSL4inhibitor with an IC50 of 0.33  μM. LIBX-A402 significantly protects MDA-MB-231 and LUHMES cells from ferroptosis. LIBX-A402 can be used for cancer, ischemia-reperfusion injury and neurodegenerative diseases like Parkinson’s disease research.
    LIBX-A402
  • HY-175395
    Onychocin B 98%
    Onychocin B is a cyclic tetrapeptide isolated from Onychocola sclerotica. Onychocin B is a calcium channel blocker with an IC50 of 7.1 μM for Cav1.2.
    Onychocin B
  • HY-175441
    Carbonic anhydrase activator 1 2374923-30-3
    Carbonic anhydrase activator 1 (Compound 17) is an orally active and a BBB-penetrable Carbonic anhydrase (CA) activator with KAs of 7.8, 3.9  and 2.1 μM for hCA I, hCA VA and hCA VII. Carbonic anhydrase activator 1 can be used for cancers, glaucoma, cardiovascular diseases and neurodegenerative disorders like epilepsy research.
    Carbonic anhydrase activator 1
  • HY-175540
    PDGFRα kinase-IN-2 3066103-58-7 98%
    PDGFRα kinase-IN-2 is a potent PDGFR-α inhibitor with an IC50 of 2.1 nM. PDGFRα kinase-IN-2 exhibits anticancer activity against human colon cancer HT-29 cell with an IC50 of 1.48 μM. PDGFRα kinase-IN-2 has anti-angiogenic activity in zebrafish models and low embryonic lethality. PDGFRα kinase-IN-2 can used for the studies of colon cancer and anti-angiogenesis.
    PDGFRα kinase-IN-2
  • HY-17557R
    Calcium N5-methyltetrahydrofolate (Standard) 26560-38-3 98%
    Calcium N5-methyltetrahydrofolate (Standard) is the analytical standard of Calcium N5-methyltetrahydrofolate. This product is intended for research and analytical applications. 0
    Calcium N5-methyltetrahydrofolate (Standard)
  • HY-175593
    M6766 696628-90-7 98%
    M6766 is a selective endoplasmic reticulum oxidoreductase 1α (ERO1α) inhibitor with an IC50 of 1.4 μM and a KD of 1.1 μM. M6766 also inhibits ERO1β with an IC50 of 7.2 μM. M6766 binds to the flavin adenine dinucleotide-binding pocket in ERO1α. M6766 inhibits granule secretion, αIIbβ3 integrin activation, Ca2+ mobilization, and platelet aggregation. M6766 can be used for the research of neurological disease, such as ischemic stroke.
    M6766
  • HY-175599
    Z6466608628 2869183-63-9
    Z6466608628 is a selective PPIL4 molecular glue degrader with an EC50 of 0.34  μM. PPIL4 is a regulator of the BACR spliceosome and it is essential for brain angiogenesis. Z6466608628 can be used for intracranial aneurysm (IA) research.
    Z6466608628
  • HY-175640
    Troponin-IN-1
    Troponin-IN-1 is a troponin inhibitor. Troponin-IN-1 protects OGD/R-injured H9c2 cardiomyocytes by reducing LDH leakage, pyroptosis and ROS accumulation. Troponin-IN-1 inhibits NO production and IL-1β/TNF-α/IL-18 release in LPS (HY-D1056)-induced RAW264.7 cells. Troponin-IN-1 acts via caspase-1/GSDMD/IL-18 pathway. Troponin-IN-1 reduces myocardial infarct size in LAD-induced myocardial ischemia/reperfusion (MI/R) male rats. Troponin-IN-1 can be used for the study of myocardial ischemia/reperfusion (MI/R) injury.
    Troponin-IN-1
Cat. No. Product Name / Synonyms Application Reactivity